Five-year analysis of the activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme.

OBJECTIVES

The Surveillance of Tedizolid Activity and Resistance (STAR) programme monitored the tedizolid activity against , , , and group. We evaluated the antimicrobial susceptibility of 47 400 unique Gram-positive clinical isolates from the STAR programme collected from USA (21 243), Europe (17 674), Asia-Pacific (4954) and Latin America (3529) medical centres (2015-19).

METHODS

All isolates were tested for susceptibility by reference broth microdilution method. WGS and analysis were performed on linezolid-non-susceptible (NS) isolates.

RESULTS

Tedizolid was active against ≥99.9% of (100.0% of MSSA and >99.9% of MRSA), , , and group isolates, with MIC values ranging from 0.12 to 0.25 mg/L and MIC values of 0.25 mg/L. Linezolid, vancomycin and daptomycin were also active agents against these organisms. Tedizolid inhibited all VRE and 73.1% of linezolid-NS isolates. Ampicillin and daptomycin retained 100.0% activity against VRE and linezolid-NS isolates. Linezolid-NS isolates carried mostly the gene. G2576T alterations in the 23S rRNA were observed in one linezolid-NS isolate and one linezolid-NS isolate.

CONCLUSIONS

No resistance trends were observed for tedizolid during the study period.